Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 9Terminated 5Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Ovarian Neoplasms 35Breast Neoplasms 32Lung Neoplasms 28Uterine Cervical Neoplasms 18Triple Negative Breast Neoplasms 15Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Small Cell Lung Carcinoma 13Squamous Cell Carcinoma of Head and Neck 10Neuroblastoma 10Esophageal Neoplasms 10Esophageal Squamous Cell Carcinoma 8Central Nervous System Neoplasms 8Recurrence 7Head and Neck Neoplasms 6Endometrial Neoplasms 6Retinoblastoma 5Neoplasm Metastasis 5Brain Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 4Melanoma 4Carcinoma, Squamous Cell 4Testicular Neoplasms 3Oligodendroglioma 3Medulloblastoma 3Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Glioblastoma 3

Interventions

Docetaxel 5Pemetrexed 4Capecitabine 4pembrolizumab 3Oxaliplatin 3icotinib 2Radiation 2Paclitaxel 2Gemcitabine 2Gefitinib 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Carboplatin 2sintilimab 1rucaparib 1regorafenib 1olaparib 1lenvatinib 1iron isomaltoside 1000 1ipatasertib 1iopromide 1gluconic acid 1elemene 1capecitabine-irinotecan combination 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma × Carboplatin × Clear all
NCT02509286 2024-05-08

ESOPEC

University Hospital Schleswig-Holstein

Phase 3 Unknown
438 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡